Ustekinumab
- Generic Name
- Ustekinumab
- Brand Names
- Stelara, Pyzchiva, Uzpruvo, Wezenla, Steqeyma, Otulfi, Fymskina, Eksunbi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 815610-63-0
- Unique Ingredient Identifier
- FU77B4U5Z0
- Background
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMAR...
- Indication
Ustekinumab is indicated for the management of moderate to severe plaque psoriasis in patients 6 years of age and older who are candidates for phototherapy or systemic therapy. In adult patients, it is also indicated for the management of active psoriatic arthritis (PsA) alone or in combination with methotrexate, moderately to severely active Crohn’s disease...
- Associated Conditions
- Severe Plaque psoriasis, Ulcerative Colitis, Active Severe, Active Psoriatic arthritis, Moderate Plaque psoriasis, Moderate Ulcerative colitis, Moderate, active Crohn´s Disease, Severe, active Crohn´s Disease
- Associated Therapies
- -
Ustekinumab for the Treatment of Giant Cell Arteritis
- Conditions
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT02955147
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 8
- Registration Number
- NCT02911116
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 388
- Registration Number
- NCT02877134
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1114
- Registration Number
- NCT02826603
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 357
- Registration Number
- NCT02763969
- Locations
- 🇦🇺
Local Institution, Melbourne, Australia
The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab)
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02693470
- Locations
- 🇨🇳
Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Kaohsiung, Taiwan
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 577
- Registration Number
- NCT02684357
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 560
- Registration Number
- NCT02684370
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 302
- Registration Number
- NCT02561806
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada
🇬🇧For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salford, United Kingdom
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
- First Posted Date
- 2015-01-01
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT02330380
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.